173 related articles for article (PubMed ID: 20881645)
1. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
Gitlitz BJ; Moon J; Glisson BS; Reimers HJ; Bury MJ; Floyd JD; Schulz TK; Sundaram PK; Ho C; Gandara DR
J Thorac Oncol; 2010 Nov; 5(11):1835-40. PubMed ID: 20881645
[TBL] [Abstract][Full Text] [Related]
2. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Lara PN; Moon J; Redman MW; Semrad TJ; Kelly K; Allen JW; Gitlitz BJ; Mack PC; Gandara DR
J Thorac Oncol; 2015 Jan; 10(1):110-5. PubMed ID: 25490004
[TBL] [Abstract][Full Text] [Related]
3. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
Wakelee HA; Lee JW; Hanna NH; Traynor AM; Carbone DP; Schiller JH
J Thorac Oncol; 2012 Oct; 7(10):1574-82. PubMed ID: 22982658
[TBL] [Abstract][Full Text] [Related]
4. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
Miller AA; Pang H; Hodgson L; Ramnath N; Otterson GA; Kelley MJ; Kratzke RA; Vokes EE;
J Thorac Oncol; 2010 Mar; 5(3):380-4. PubMed ID: 20087228
[TBL] [Abstract][Full Text] [Related]
7. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Matei D; Sill MW; Lankes HA; DeGeest K; Bristow RE; Mutch D; Yamada SD; Cohn D; Calvert V; Farley J; Petricoin EF; Birrer MJ
J Clin Oncol; 2011 Jan; 29(1):69-75. PubMed ID: 21098323
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Lara PN; Chansky K; Davies AM; Franklin WA; Gumerlock PH; Guaglianone PP; Atkins JN; Farneth N; Mack PC; Crowley JJ; Gandara DR
J Thorac Oncol; 2006 Nov; 1(9):996-1001. PubMed ID: 17409985
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Williamson SK; Moon J; Huang CH; Guaglianone PP; LeBlanc M; Wolf GT; Urba SG
J Clin Oncol; 2010 Jul; 28(20):3330-5. PubMed ID: 20498388
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
Srkalovic G; Hussein MA; Hoering A; Zonder JA; Popplewell LL; Trivedi H; Mazzoni S; Sexton R; Orlowski RZ; Barlogie B
Cancer Med; 2014 Oct; 3(5):1275-83. PubMed ID: 24913924
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Bellmunt J; Maroto-Rey P; Trigo JM; Carles J; Guillem V; López-Martín JA; Antón-Torres A; Urruticoechea L
Clin Transl Oncol; 2010 Jul; 12(7):503-8. PubMed ID: 20615828
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Huo D; Elit L; Knost JA; Wade JL; Agamah E; Vokes EE; Fleming GF
Gynecol Oncol; 2010 Apr; 117(1):37-40. PubMed ID: 20117828
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
Sridhar SS; Winquist E; Eisen A; Hotte SJ; McWhirter E; Tannock IF; Mukherjee SD; Wang L; Blattler C; Wright JJ; Moore MJ
Invest New Drugs; 2011 Oct; 29(5):1045-9. PubMed ID: 20191303
[TBL] [Abstract][Full Text] [Related]
17. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
19. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Schwandt A; von Gruenigen VE; Wenham RM; Frasure H; Eaton S; Fusco N; Fu P; Wright JJ; Dowlati A; Waggoner S
Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
